Stockreport

Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

Karuna Therapeutics, Inc.  (KRTX) 
PDF BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potent [Read more]